Larimar Therapeutics (LRMR) Market Capitalization (2020 - 2026)

Larimar Therapeutics (LRMR) has reported Market Capitalization for 7 consecutive years, with $316.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization rose 71.23% year-over-year to $316.8 million; the trailing twelve-month figure through Jun 2026 stood at $316.8 million (up 71.23% YoY), and the FY2025 full-year result was $316.6 million, up 28.19% from the prior year.
• Market Capitalization held at $316.8 million in Q2 2026 per LRMR's latest filing, from $316.6 million in the prior quarter.
• Across five years, Market Capitalization topped out at $484.2 million in Q1 2024 and bottomed at $34.7 million in Q2 2022.
• Historically, Market Capitalization has averaged $225.5 million across 5 years, with a median of $196.0 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Market Capitalization sank 77.0% in 2022, then jumped 290.16% in 2023.
• Over 5 years, Market Capitalization stood at $106.4 million in 2022, then jumped by 87.78% to $199.8 million in 2023, then grew by 23.61% to $247.0 million in 2024, then gained by 28.19% to $316.6 million in 2025, then climbed by 0.08% to $316.8 million in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $316.8 million, $316.6 million, and $276.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.